Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth R Plimack

Showing results (1-10 of 209) with videos related to

Pageof 21
Sort By:
Immunotherapy|March 23, 2018
Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brakeMatthew Zibelman, Elizabeth R Plimack
European Urology|September 5, 2022
Adding a Fourth Modality to Trimodal Therapy for Muscle-invasive Bladder CancerPooja Ghatalia, Elizabeth R Plimack
Nature Reviews. Clinical Oncology|September 4, 2023
Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinomaPooja Ghatalia, Elizabeth R Plimack
Oncology (Williston Park, N.Y.)|February 19, 2016
Checkpoint Inhibitors and Urothelial Carcinoma: The Translational ParadigmMatthew Zibelman, Elizabeth R Plimack
Current Urology Reports|November 9, 2018
Immunotherapy for Urothelial Carcinoma: Current Evidence and Future DirectionsAbhishek Tripathi, Elizabeth R Plimack
Journal of the National Comprehensive Cancer Network : JNCCN|June 10, 2017
Integrating Immunotherapy Into the Management of Renal Cell CarcinomaMatthew Zibelman, Elizabeth R Plimack
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
Integration of Immunotherapy Into the Treatment of Advanced Urothelial CarcinomaPooja Ghatalia, Elizabeth R Plimack
Annals of Translational Medicine|October 3, 2019
Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?Matthew Zibelman, Elizabeth R Plimack
Future Oncology (London, England)|July 13, 2016
Systemic therapy for bladder cancer finally comes into a new ageMatthew Zibelman, Elizabeth R Plimack
Bladder Cancer (Amsterdam, Netherlands)|February 13, 2018
Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder CancerPhilip H Abbosh, Elizabeth R Plimack
Pageof 21

Showing results (1-10 of 209) with videos related to

Sort By:
Pageof 21
Immunotherapy|March 23, 2018
Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brakeMatthew Zibelman, Elizabeth R Plimack
European Urology|September 5, 2022
Adding a Fourth Modality to Trimodal Therapy for Muscle-invasive Bladder CancerPooja Ghatalia, Elizabeth R Plimack
Nature Reviews. Clinical Oncology|September 4, 2023
Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinomaPooja Ghatalia, Elizabeth R Plimack
Oncology (Williston Park, N.Y.)|February 19, 2016
Checkpoint Inhibitors and Urothelial Carcinoma: The Translational ParadigmMatthew Zibelman, Elizabeth R Plimack
Current Urology Reports|November 9, 2018
Immunotherapy for Urothelial Carcinoma: Current Evidence and Future DirectionsAbhishek Tripathi, Elizabeth R Plimack
Journal of the National Comprehensive Cancer Network : JNCCN|June 10, 2017
Integrating Immunotherapy Into the Management of Renal Cell CarcinomaMatthew Zibelman, Elizabeth R Plimack
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
Integration of Immunotherapy Into the Treatment of Advanced Urothelial CarcinomaPooja Ghatalia, Elizabeth R Plimack
Annals of Translational Medicine|October 3, 2019
Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?Matthew Zibelman, Elizabeth R Plimack
Future Oncology (London, England)|July 13, 2016
Systemic therapy for bladder cancer finally comes into a new ageMatthew Zibelman, Elizabeth R Plimack
Bladder Cancer (Amsterdam, Netherlands)|February 13, 2018
Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder CancerPhilip H Abbosh, Elizabeth R Plimack
Pageof 21